Stock listing

NASDAQ:APMD Apnimed, Inc. Stock

Home listing (NASDAQ) of Apnimed, Inc.

Follow Apnimed, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:APMD

$16.09 USD -1.36 (-7.8%)

Close on Nov 20, 2026

Past 3 months +0.6% · daily closes, Jul 29, 2026 – Nov 20, 2026, adjusted for splits
Day range
$15.95 – $17.73 USDNov 20, 2026
Volume
248,586 sharesNov 20, 2026
Market cap
$669.8M USDAt the close on Nov 20, 2026 · price × 41.63M shares outstanding
Traded on an average day
$10.22M USDMedian day 340,300 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:APMD · Home$16.09 USD-1.36 (-7.8%)248,586$17.08$17.73$15.95$17.45Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:APMD · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$16.09-1.36-7.8%$17.08$17.73$15.95248,586
$17.45-0.35-2.0%$17.80$19.06$17.41296,982
$17.80+1.52+9.3%$16.03$17.89$15.86395,528
$16.28-0.64-3.8%$16.05$17.10$15.80256,887
$16.92+0.29+1.7%$17.41$17.46$16.38690,802
$16.63-0.15-0.9%$16.81$16.99$16.16278,599
$16.78+0.92+5.8%$15.99$16.85$15.26194,866
$15.86+0.05+0.3%$15.67$16.58$15.21378,259
$15.81+0.71+4.7%$15.32$16.22$15.09290,121
$15.10+0.94+6.6%$14.26$15.41$14.11225,337
$14.16-1.14-7.5%$15.37$15.52$13.88447,702
$15.30+0.24+1.6%$15.36$15.97$14.65603,554
$15.06-0.34-2.2%$15.48$16.99$14.96575,729
$15.40-1.00-6.1%$16.55$16.78$15.09530,944
$16.40-0.94-5.4%$17.10$17.36$16.16465,684
$17.34-1.81-9.5%$19.15$19.19$17.001,011,662
$19.15-0.34-1.7%$19.44$19.51$18.00323,307
$19.49+0.54+2.8%$19.06$19.75$18.23365,456
$18.95-0.04-0.2%$19.14$19.52$18.43178,483
$18.99+0.46+2.5%$18.50$19.15$17.84277,300
$18.53-0.37-2.0%$18.75$19.24$18.22194,811
$18.90+0.39+2.1%$18.75$19.57$18.57295,456
$18.51+1.915+11.5%$16.64$18.80$16.43311,107
$16.60-1.165-6.6%$18.00$18.49$16.52264,469
$17.76-0.49-2.7%$18.30$18.35$17.40235,100
$18.25+1.02+5.9%$17.25$18.76$17.25260,200
$17.23-0.60-3.4%$17.85$18.62$17.001,012,700
$17.83-0.80-4.3%$18.85$18.85$17.45215,600
$18.63+0.11+0.6%$18.57$20.00$18.26301,100
$18.52+0.30+1.6%$18.18$19.54$17.80268,300
$18.22+0.18+1.0%$18.05$18.61$17.38332,000
$18.04-0.61-3.3%$18.66$19.40$17.84465,600
$18.65-3.10-14.3%$21.95$21.95$18.34580,800
$21.75+0.24+1.1%$21.70$22.11$21.10340,300
$21.51-1.03-4.6%$22.60$22.73$21.10681,800
$22.54+0.63+2.9%$21.96$24.50$21.96747,400
$21.91-1.99-8.3%$23.57$24.50$21.49668,800
$23.90+2.23+10.3%$21.48$24.29$21.48669,500
$21.67+0.58+2.8%$21.15$22.09$19.80283,800
$21.09-0.54-2.5%$22.00$22.77$20.68298,700
$21.63-0.86-3.8%$22.06$22.85$20.50398,200
$22.49-3.02-11.8%$25.44$25.44$21.60858,100
$25.51-0.71-2.7%$26.41$26.69$24.42624,000
$26.22-2.78-9.6%$28.90$28.90$23.131,507,000
$29.00+0.89+3.2%$28.34$30.22$27.993,141,800
$28.11+1.02+3.8%$27.47$29.00$27.15355,700
$27.09+1.53+6.0%$25.81$27.96$25.66552,600
$25.56+0.010.0%$25.62$26.83$25.05350,400
$25.55-0.68-2.6%$26.48$27.07$25.05263,400
$26.23-0.57-2.1%$27.07$27.72$26.19207,800
$26.80-1.28-4.6%$27.11$28.74$26.59213,400
$28.08-0.71-2.5%$28.79$29.46$27.34220,000
$28.79+1.34+4.9%$27.67$29.65$27.41380,800
$27.45-0.36-1.3%$27.36$28.36$26.44232,900
$27.81-0.02-0.1%$28.11$28.83$27.32234,300
$27.83+0.98+3.6%$27.00$28.75$26.90276,600
$26.85+0.60+2.3%$26.11$27.88$25.11376,500
$26.25-3.46-11.6%$29.71$30.07$25.60475,600
$29.71+0.99+3.4%$29.01$32.37$28.83536,100
$28.72-0.86-2.9%$29.50$31.09$28.33421,700
$29.58+2.21+8.1%$27.59$30.19$26.86334,000
$27.37+1.74+6.8%$26.60$29.56$26.01480,600
$25.63-2.40-8.6%$27.82$27.83$25.33244,400
$28.03-0.52-1.8%$28.60$29.56$27.64245,300
$28.55-3.48-10.9%$31.87$31.97$28.39433,800
Ticker
NASDAQ:APMD
Asset type
Stock
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Apnimed, Inc. news

Apnimed, Inc. on 6ix

News releases
9 in the last 12 months · 9 in all · newest Nov 19, 2026 · oldest 2026
Decks
15 decks · latest September 2026

Where Apnimed, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:APMD · Home listing · This pageNASDAQUnited StatesUSD
BOATS:APMDBOATSUnited StatesUSD

Valuation

Statements: Year to Dec 31, 2025 · balance Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$357.1M USD
P/E
Loss
EV/sales
9.3×
EV/EBITDA
Negative EBITDA
Price/book
2.4×
Gross margin
82.6%
Operating margin
−139.9%
Net margin
−2.4%
Debt to equity
0.1×
Beta vs S&P 500
Under 6 months of closes

Forecasts

4 strong buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.

Price target
50.00 USD · Analysts' mean
EPS, year to Dec 2026
1.07 · 1 analyst
Revenue, year to Dec 2026
99.37M · 1 analyst

Team and board

OfficerRole
Kevin R. LindChief Executive Officer
Michael KellyChief Financial Officer
Dennis MolnarPresident and Chief Operating Officer
Steven SpectorChief Legal Officer and Head of Corporate Affairs
Andrea WernerSenior Vice President, Global Clinical Operations
Jennifer PattersonSenior Vice President, Human Resources
John YeeSenior Vice President, Medical Affairs
Barry WohlChief Business Officer
Beth WeinbergChief Regulatory and Safety Officer
Graham GoodrichChief Commercial Officer
John CroninChief Medical Officer
Luigi Taranto MontemurroChief Scientific Officer

Events

QuarterResultsShare move
Q3 2026Nov 16, 2026 · Before open−3.8%
Q2 2026Sep 8, 2026 · After close−2.5%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck28 slidesSeptember 2026
Investor Presentation (July 2025)Investor deck21 slidesJuly 2025
Investor Presentation (May 2025)Investor deck22 slidesMay 2025
Investor Presentation (April 2025)Investor deck29 slidesApril 2025
Investor Presentation (January 2025)Investor deck28 slidesJanuary 2025
Investor Presentation (December 2024)Investor deck24 slidesDec 2, 2024
Investor Presentation (May 2024)Investor deck20 slidesMay 2024
Investor Presentation (March 2024)Investor deck20 slidesMarch 2024
Investor Presentation (January 2024)Investor deck20 slidesJanuary 2024
Investor Presentation (November 2023)Investor deck17 slidesNovember 2023
All 15 decks
DeckKindSlidesDate
Investor Presentation (September 2023)Investor deck17 slidesSeptember 2023
Investor Presentation (April 2023)Investor deck16 slidesApril 2023
Investor Presentation (January 2023)Investor deck18 slidesJanuary 2023
Investor Presentation (November 2022)Investor deck20 slidesNovember 2022
JPMorgan Healthcare Conference 2022Conference21 slidesJanuary 2022

Open Decks

Financings

RaiseDate
Public offering of common stock
Closed: US$220.8M in the latest tranche · US$16 a share · BofA Securities +3
Dealers: BofA Securities (co-lead), Evercore ISI (co-lead), Cantor (co-lead), LifeSci Capital (co-lead)
Use of proceeds: To support commercial readiness and the potential U.S. launch of Oxnimbi, if approved by the FDA
Sep 8, 2026

Open Financings · Read by 6ix AI from the company's releases

IPO

Priced at US$16.00 a share on Jul 30, 2026.

Price
US$16.00 a share
Shares offered
12,000,000 shares of common stock
Offering size
US$192 million
Underwriters' option
Up to 1,800,000 more shares
Listing
APMD on the Nasdaq Global Select Market
Underwriters
BofA Securities, Evercore ISI, Cantor, LifeSci Capital · In the order on the cover
Shares delivered
On or about Aug 3, 2026

Steps

StepWhen
Draft sent to the SEC in confidenceJul 1, 2024
Filed publiclyJul 10, 2026
Amended onceJul 27, 2026
Shares registered with an exchangeJul 29, 2026
Declared effective by the SECJul 30, 2026
Final prospectus, with the priceJul 31, 2026

Open IPO · From the cover of the final prospectus (424B4) filed Jul 31, 2026

Financials

Annual, in USD

Income statement

LineFY2025FY2024
Revenue38.5M8.01M
Cost of revenue6.69M3.37M
Gross profit31.8M4.64M
Research and development62.1M97.4M
Selling, general and administrative23.5M21.5M
Operating income-53.8M-114.2M
Depreciation and amortization27.0K23.0K
EBITDA-53.8M-114.2M
Income before tax-932.0K-108.5M
Net income-932.0K-111.3M
Earnings per share, basic-0.03-2.79

Balance sheet

LineFY2025FY2024
Cash and equivalents41.9M68.3M
Receivables959.0K1.11M
Current assets45.1M73.2M
Total assets72.9M109.2M
Accounts payable1.79M3.58M
Current liabilities110.9M42.4M
Long-term debt40.6M
Total debt41.5M
Total liabilities445.7M357.8M
Shareholders' equity-372.8M-248.6M
Shares outstanding26.6M39.8M

Cash flow

LineFY2025FY2024
Cash from operations-77.8M-110.2M
Capital spending0-70.0K
Free cash flow-77.8M-110.3M
Cash from financing51.4M51.0K
Change in cash-26.5M41.8M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 16, 2026Quarterly reportSEC
8-K · Current reportNov 16, 2026ResultsSEC
10-Q/A · Quarterly report, amendedNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 13, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeNov 4, 2026Big-stake noticeSEC
S-8 · Registration statement for employee plansSep 8, 2026Offer documentSEC
10-Q · Quarterly reportSep 8, 2026Quarterly reportSEC
8-K · Current reportSep 8, 2026ResultsSEC
All 61 filings
FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeAug 7, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeAug 6, 2026Big-stake noticeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 5, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
4 · Change in ownershipAug 3, 2026Insider tradeSEC
8-K · Current reportAug 3, 2026Current reportSEC
S-8 · Registration statement for employee plansJul 31, 2026Offer documentSEC
424B4 · ProspectusJul 31, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 31, 2026Other filingsSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
S-1MEF · Registration of more shares for the same offeringJul 30, 2026Offer documentSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
3 · Initial statement of ownershipJul 30, 2026Insider tradeSEC
CERT · Exchange's certificate of listingJul 30, 2026Other filingsSEC
8-A12B · Registration of shares for listing on an exchangeJul 29, 2026Other filingsSEC
S-1/A · Registration statement, amendedJul 27, 2026Offer documentSEC
S-1 · Registration statementJul 10, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedMay 29, 2026Offer documentSEC
DRS/A · Draft registration statement, amendedApr 21, 2026Offer documentSEC
DMar 26, 2026Other filingsSEC
DRS/A · Draft registration statement, amendedFeb 17, 2026Offer documentSEC
D/ADec 8, 2025Other filingsSEC
D/AOct 1, 2025Other filingsSEC
DSep 24, 2025Other filingsSEC
DApr 24, 2025Other filingsSEC
DRS · Draft registration statementJul 1, 2024Offer documentSEC
DNov 8, 2023Other filingsSEC
DDec 23, 2022Other filingsSEC
D/ANov 1, 2022Other filingsSEC
DMay 10, 2022Other filingsSEC
DMar 25, 2021Other filingsSEC
DApr 7, 2020Other filingsSEC
D/AAug 7, 2019Other filingsSEC
D/AJan 10, 2019Other filingsSEC
D/AAug 9, 2018Other filingsSEC
DJul 6, 2018Other filingsSEC

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Apnimed, Inc.’s releases · as of Sep 30, 2026

Common shares
41,630,779
Fully diluted
41,630,779

Fully diluted

LineSharesAs of
Common shares41,630,779Sep 4, 2026

Share count over time

CountShares
Sep 4, 202641,630,779

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ameriprise7.78M18.7%US$170MSep 30, 2026
Alpha Wave Global, LP7.05M16.9%US$155MSep 30, 2026
Tao Capital Management LP2.18M5.2%US$47.7MSep 30, 2026
Janus Henderson1.56M3.8%US$34.2MSep 30, 2026
JPMorgan1.44M3.5%US$34.4MSep 30, 2026
Nexpoint Asset Management, L.P.1.27M3.1%US$27.9MSep 30, 2026
Logos Global Management LP1.1M2.6%US$24.1MSep 30, 2026
Jennison Associates LLC1.08M2.6%US$23.7MSep 30, 2026
abrdn945K2.3%US$20.7MSep 30, 2026
Sectoral Asset Management Inc942K2.3%US$20.6MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
Orbimed Advisors LLC925K2.2%US$20.3MSep 30, 2026
BlackRock855K2.1%US$18.7MSep 30, 2026
Vanguard723K1.7%US$15.8MSep 30, 2026
AllianceBernstein580K1.4%US$12.7MSep 30, 2026
Citadel518K1.2%US$11.3MSep 30, 2026
Geode Capital320K0.77%US$7.01MSep 30, 2026
Woodline Partners LP283K0.68%US$6.2MSep 30, 2026
Fidelity280K0.67%US$6.14MSep 30, 2026
Bank of America264K0.63%US$5.78MSep 30, 2026
Integral Health Asset Management, LLC225K0.54%US$4.93MSep 30, 2026
State Street213K0.51%US$4.67MSep 30, 2026
UBS182K0.44%US$3.98MSep 30, 2026
Masters Capital Management LLC125K0.30%US$2.74MSep 30, 2026
Ghisallo Capital Management LLC125K0.30%US$2.74MSep 30, 2026
Crcm LP118K0.28%US$2.58MSep 30, 2026
Schwab111K0.27%US$2.43MSep 30, 2026
Parkman Healthcare Partners LLC105K0.25%US$2.31MSep 30, 2026
Adage Capital Partners Gp, L.L.C.99,2550.24%US$2.17MSep 30, 2026
Northern Trust92,0920.22%US$2.02MSep 30, 2026
Seven Grand Managers, LLC73,7500.18%US$1.62MSep 30, 2026
Kayne Anderson Rudnick Investment Management LLC46,8200.11%US$1.03MSep 30, 2026
BNY25,8690.06%US$567KSep 30, 2026
Legal & General24,1490.06%US$529KSep 30, 2026
Schonfeld Strategic Advisors LLC21,6450.05%US$474KSep 30, 2026
Morgan Stanley21,3260.05%US$467KSep 30, 2026
Nuveen15,6190.04%US$342KSep 30, 2026
Rhumbline Advisers12,0940.03%US$265KSep 30, 2026
Invesco11,1840.03%US$245KSep 30, 2026
DWS10,5120.03%US$230KSep 30, 2026
Magnetar Financial LLC10,4480.03%US$229KSep 30, 2026
D. E. Shaw & Co., Inc.10,4020.02%US$228KSep 30, 2026
Cerity Partners LLC10,2120.02%US$224KSep 30, 2026
T. Rowe Price10,1720.02%US$223KSep 30, 2026
Two Sigma10,1000.02%US$221KSep 30, 2026
MetLife Investment Management, LLC7,3220.02%US$160KSep 30, 2026
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.5,8930.01%US$129KSep 30, 2026
Bellevue Group AG4,9190.01%US$108KSep 30, 2026
Wells Fargo4,2210.01%US$92,482Sep 30, 2026
Strs Ohio3,300<0.01%US$72,303Sep 30, 2026
Tower Research Capital LLC (TRC)3,172<0.01%US$69,499Sep 30, 2026

This page holds 50 of 68 holders. Open Shareholders

Insider trades

TradeTradeSharesPriceValueDate
Morningside Venture Investments Ltd
10% owner
Buy312,500USD 16.00US$5MAug 3, 2026
Sekhri Paul J
Director
Buy12,500USD 16.00US$200KAug 3, 2026

Big stakes

StakeStakeSharesDateFiling
Ameriprise Financial Inc18.90%7.48MJul 31, 2026Schedule 13G
Morningside Venture Investments Ltd17.40%7.23MSep 30, 2026Schedule 13G
SHIONOGI & CO LTD7.10%2.95MSep 30, 2026Schedule 13G
Miller Lawrence G.6.20%2.71MSep 30, 2026Schedule 13G
Tao Capital Management LP5.20%2.18MJul 31, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Paul Sekhri
Other companies: vTv Therapeutics Inc. (Chairman of the Board, President and Chief Executive Officer · Since at least Aug 1, 2022); Veeva Systems Inc. (Director · Since at least Jun 22, 2016); Axcella Health Inc (Director · May 19, 2022 – May 19, 2022 · Past); Longboard Pharmaceuticals Inc (Director · Mar 11, 2021 – Dec 2, 2024 · Past); BiomX Inc. (Director · Oct 2, 2020 – Jul 28, 2021 · Past); Enumeral Biomedical Holdings Inc (Director · Dec 9, 2016 – Dec 9, 2016 · Past); Alpine Immune Sciences Inc (Director · Sep 12, 2016 – Jan 2, 2020 · Past)
Director · Since at least Jul 30, 2026
Paul Fonteyne
Other companies: Amylyx Pharmaceuticals, Inc. (Director · Since at least Jan 6, 2022); Apellis Pharmaceuticals, Inc. (Director · Since at least Apr 2, 2020); Covetrus Inc (Director · Jul 1, 2021 – Oct 13, 2022 · Past); AMAG Pharmaceuticals Inc (Director · Oct 8, 2019 – Nov 16, 2020 · Past); Adicet Bio, Inc. (Director · Jan 25, 2018 – Jun 3, 2020 · Past)
Director · Since at least Jul 30, 2026
Kevin Lind
Other companies: Avalo Therapeutics, Inc. (Director · Since at least Sep 22, 2025); Longboard Pharmaceuticals Inc (President and CEO, Director · Mar 11, 2021 – Dec 2, 2024 · Past); Arena Pharmaceuticals Inc (Executive VP and CFO · Jun 15, 2016 – Mar 1, 2020 · Past)
Chief Executive Officer · Since at least Jul 30, 2026
John Yee
Other companies: Tempest Therapeutics, Inc. (Director · Since at least Jun 4, 2026)
Senior Vice President, Medical Affairs · Since at least Nov 5, 2026
Andrea WernerSenior Vice President, Global Clinical Operations · Since at least Nov 5, 2026
Barry WohlChief Business Officer · Since at least Nov 5, 2026
Beth WeinbergChief Regulatory and Safety Officer · Since at least Nov 4, 2026
Dennis MolnarPresident and Chief Operating Officer · Since at least Jul 30, 2026
Graham GoodrichChief Commercial Officer · Since at least Nov 5, 2026
Jennifer PattersonSenior Vice President, Human Resources · Since at least Nov 5, 2026
All 15 people
PersonSeat
John CroninChief Medical Officer · Since at least Nov 5, 2026
Lawrence G MillerDirector · Since at least Jul 30, 2026
Luigi Taranto MontemurroChief Scientific Officer · Since at least Nov 5, 2026
Michael KellyChief Financial Officer · Since at least Jul 30, 2026
Steven SpectorChief Legal Officer and Head of Corporate Affairs · Since at least Sep 8, 2026

Open People

Log in to ask 6ix AI your own questions about Apnimed, Inc.